LP-IR Score

Your fasting glucose looks fine. Your standard cholesterol panel comes back normal. But underneath those reassuring numbers, your body may already be struggling to respond to insulin, the hormone that moves sugar out of your blood and into your cells. By the time fasting glucose or HbA1c starts to climb, insulin resistance has often been building for years. The LP-IR Score (Lipoprotein Insulin Resistance Score) is designed to catch that silent shift much earlier, by reading patterns in your cholesterol-carrying particles that change long before blood sugar does.

LP-IR is not a single molecule you can point to under a microscope. It is a calculated score, ranging from 0 (most insulin sensitive) to 100 (most insulin resistant), derived from a specialized blood test called NMR spectroscopy. The test measures the sizes and concentrations of six types of lipoprotein particles, the tiny packages that ferry fats through your bloodstream. When your body stops responding well to insulin, the mix of those particles shifts in predictable ways: certain particles get larger or more numerous, while others shrink or become scarce. LP-IR captures that entire pattern in a single number.

What Goes Into the Score

The six lipoprotein measurements that feed into LP-IR each carry a different weight, reflecting how strongly each one tracks with insulin resistance. The biggest contributor is the average size of VLDL particles, the fat-rich packages your liver releases into the bloodstream. In insulin-resistant states, the liver pumps out larger, more triglyceride-loaded VLDL particles, so bigger average VLDL size pushes the score up. The concentration of large VLDL particles carries the second-highest weight for the same reason.

On the protective side, large HDL particles (often called "good cholesterol" carriers) and larger average HDL size are associated with insulin sensitivity. When insulin resistance develops, you tend to lose large HDL particles and end up with smaller ones. Finally, the number and size of small, dense LDL particles contribute modestly. More small LDL particles and a smaller average LDL size both nudge the score upward. Together, these six measurements create a metabolic fingerprint that reflects how well your body is handling insulin.

Type 2 Diabetes Risk

The strongest evidence for LP-IR's value is in predicting who will develop type 2 diabetes. In a study of roughly 6,000 adults without diabetes (the PREVEND study), those in the highest quarter of LP-IR scores were about 10 times more likely to develop diabetes over 7.5 years compared to those in the lowest quarter. Even after accounting for BMI, family history, blood pressure, and standard lipids, the highest-scoring group still faced about 3 times the risk.

A larger study followed nearly 26,000 women for over 20 years (the Women's Health Study). Each standard-deviation increase in LP-IR was associated with roughly double the diabetes risk after adjusting for demographics and lifestyle. When the researchers controlled for HbA1c, triglycerides, HDL cholesterol, and other metabolic markers, LP-IR still independently predicted diabetes, with about a 41% higher risk per standard-deviation increase. Among all the markers tested, LP-IR had the strongest link to diabetes after HbA1c itself.

Perhaps most striking: LP-IR predicted new diabetes even in women whose clinical profiles looked optimal by conventional standards, with about a 91% higher risk per standard-deviation increase in that low-risk subgroup. This is exactly the scenario where standard labs can create a false sense of security.

Heart Disease and Artery Damage

Insulin resistance does not just raise diabetes risk. It also accelerates the buildup of plaque in your arteries. In the PREVEND study's cardiovascular analysis (about 6,200 participants, median 8.2 years), each standard-deviation increase in LP-IR was linked to a 15% higher risk of cardiovascular events after full adjustment for traditional risk factors. LP-IR also showed a strong association with subclinical atherosclerosis, the early thickening of artery walls (carotid intima-media thickness) that precedes heart attacks and strokes.

Separate research from the Women's Health Study found that among roughly 50 biomarkers examined, LP-IR had the strongest association with premature coronary heart disease, outperforming HbA1c, LDL cholesterol, and non-HDL cholesterol for heart disease occurring at younger ages. If you are focused on catching cardiovascular risk early, especially if you are under 65, LP-IR adds a layer of information that standard lipid panels miss.

Fatty Liver Disease

The liver is one of the first organs affected by insulin resistance, and LP-IR reflects that connection. In a study of 61 patients with non-alcoholic fatty liver disease (NAFLD), LP-IR correlated with the amount of fat measured in the liver. That correlation was particularly strong among patients who did not yet have diabetes (correlation coefficient of 0.60), suggesting LP-IR can signal liver fat accumulation in the earlier stages of metabolic dysfunction. Once diabetes was established, however, the correlation weakened substantially, likely because the lipoprotein patterns become more uniformly disrupted at that stage.

A Paradox in Heart Failure

One finding runs counter to the general pattern. In a study of about 1,400 patients with existing heart failure followed for nearly 14 years, higher LP-IR was actually associated with slightly lower mortality risk (about 7% lower per standard-deviation increase). This inverse relationship appears to be driven by HDL particle size, specifically, smaller HDL was protective in this population. Heart failure creates a unique metabolic environment where the usual rules about insulin resistance markers do not apply cleanly. If you have heart failure, interpret LP-IR with that context in mind.

Reference Ranges

LP-IR does not yet have universally standardized reference ranges like cholesterol or HbA1c. It is not included in major clinical guidelines, and population-specific cutpoints by age, sex, or ethnicity have not been formally published. That said, the research provides a working framework for interpretation.

These tiers are drawn from published research, particularly the PREVEND study's use of 68 as a clinical cutpoint for elevated insulin resistance. Labcorp, one of the labs that performs the test, uses somewhat different medical decision limits: below 50 (low), 50 to 80 (intermediate), and above 80 (high), based on population percentiles. Because LP-IR is measured by a single platform (NMR spectroscopy), results are more consistent across labs than for many other tests, but always compare your results within the same lab over time for the most meaningful trend.

How LP-IR Compares to Other Insulin Resistance Tests

You might wonder whether you need LP-IR if you already know your fasting insulin, HOMA-IR, or triglyceride-to-HDL ratio. Each of these captures insulin resistance from a different angle. LP-IR correlates moderately with HOMA-IR (a calculation based on fasting glucose and fasting insulin), with a correlation coefficient around 0.48 to 0.51. That means they agree roughly half the time, but each captures aspects the other misses. LP-IR's practical advantage is that it does not require a separate fasting insulin measurement, since it is derived from lipoprotein particles measured during a standard fasting blood draw.

The simple triglyceride-to-HDL cholesterol ratio, which you can calculate from any standard lipid panel, actually showed somewhat stronger associations with cardiovascular events than LP-IR in head-to-head comparisons. However, LP-IR outperformed the triglyceride-to-HDL ratio for detecting subclinical atherosclerosis, the early artery thickening that precedes clinical events. Both markers have value. LP-IR adds the most when you want to catch early arterial changes and diabetes risk before standard panels flag anything.

When added to established diabetes prediction models, LP-IR improved accuracy modestly but statistically significantly. It is not a replacement for glucose and HbA1c testing; it is an earlier signal that complements them.

When Results Can Be Misleading

No published studies have measured LP-IR's within-person biological variation (the natural day-to-day fluctuation in a healthy person). This is a real gap. Without knowing how much a single score can bounce around on its own, it is hard to know whether a small change between two readings reflects a real shift or just noise. Until that data exists, treat modest score changes (a few points in either direction) with caution.

BMI is the strongest predictor of LP-IR variability. If your weight has shifted significantly between two tests, the score change may reflect body composition more than anything else. Diabetes status also matters: LP-IR's correlation with liver fat content largely disappears in people with established diabetes, so the score may be less informative once diabetes is diagnosed.

Major surgery can drop insulin sensitivity by roughly 34% in the days following the procedure, driven by stress hormones and inflammation. Although no study has directly measured LP-IR during surgical recovery, the underlying lipoprotein particles would likely shift. Avoid testing within two to three weeks of a surgical procedure. Similarly, acute illness and corticosteroid use (even short courses) increase insulin resistance substantially and could inflate your score.

Although European guidelines state that fasting is not routinely required for standard lipid profiles, the laboratory that performs LP-IR (Labcorp is one of the labs offering it) specifies that the score is inaccurate if the patient is non-fasting. The underlying lipoprotein particle sizes may be relatively stable after meals, but VLDL particle concentrations, which carry heavy weight in the LP-IR calculation, can shift after a high-fat meal. To get a reliable LP-IR result, plan to fast for at least 8 to 12 hours before your blood draw.

Tracking Your Trend

A single LP-IR reading tells you where you stand today. A series of readings tells you where you are headed, and that trajectory is far more valuable. Insulin resistance develops gradually, often over years. Catching an upward drift from 30 to 50 to 65 gives you a chance to intervene long before you cross into the high-risk zone. Conversely, if you are making lifestyle changes to improve insulin sensitivity (exercise, weight loss, dietary shifts), tracking LP-IR over time lets you see whether those changes are actually moving the needle on lipoprotein particle patterns.

Get a baseline reading, then retest in 3 to 6 months if you are actively making changes to diet, exercise, or weight. If your score is stable and in a healthy range, annual monitoring is reasonable. If you score above 45 and are making interventions, check every 3 to 6 months until you see a clear trend. Because LP-IR lacks published biological variation data, comparing your results within the same lab and under similar conditions (same time of day, fasted for at least 8 hours) makes each comparison more reliable.

Exercise interventions in the STRRIDE trials showed LP-IR reductions of 4 to 12 points over 6 to 8 months, and bariatric surgery produced drops of 35% at 6 months and 46% at 12 months. These are the benchmarks to keep in mind when evaluating whether your own trend is moving in the right direction.